Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Economic Times
The Economic Times
Ritesh Presswala

Symbiotec Pharmalab IPO Day 2: GMP signals 34% upside — Should you subscribe?

Symbiotec Pharmalab IPO witnessed a healthy response from investors, with the overall issue subscribed 1.85 times of the 1.31 crore shares on offer.

The issue is currently commanding a grey market premium (GMP) of around 34%, pointing to expectations of a potentially strong listing gain.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.